Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,401 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SoC Clear all
Recruiting Phase 3 Interventional

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

NCT06711887
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Ianalumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Orchard Park, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT05613894
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

NCT02181257
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Interventions
Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
Combination Product · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management of Non-Healing Venous Leg Ulcers (VLUs)

NCT07510412
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
NuShield®
Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pickerington, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers

NCT03154619
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
0.1% TR 987, Placebo gel
Drug
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Los Angeles, California • North Miami Beach, Florida • Pembroke Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 26, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Results available

The CHILD Trial: Hypoplastic Left Heart Syndrome Study.

NCT03406884
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome
Interventions
c-kit+ cells
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
1 Day to 21 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Active, not recruiting Not applicable Interventional

OsteoGen Plug vs. Freeze-dried Bone Allograft With Collagen Barrier

NCT06447844
View directory record Official record
Conditions
Nonterminal Premolar Needing Extraction
Interventions
OsteoGen Plug, BioGide
Device
Lead sponsor
McGuire Institute
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Aurora, Colorado • Broomfield, Colorado • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

NCT05497284
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
LTP001, Placebo, Standard of Care (SoC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 100 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Short Stay Unit vs Hospitalization in Acute Heart Failure

NCT03302910
View directory record Official record
Conditions
Acute Heart Failure
Interventions
Short Stay Unit, Standard of Care
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 26, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

Lateral Ankle Treatment

NCT07751068
View directory record Official record
Conditions
Avulsion Fracture
Interventions
Prolonged Immobilization (Casting), Standard of Care (SOC)
Procedure
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
5 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Not yet recruiting Not applicable Interventional

Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function

NCT07414810
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
micro Sweat Test Patch (mSTP), Sweat Testing using SOC
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
2 Weeks to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

NCT02949362
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Teduglutide, SOC
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
10
States / cities
Los Angeles, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 26, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Rise With Resilience

NCT07217275
View directory record Official record
Conditions
Athletic Injuries, Sport Injuries
Interventions
Community Resiliency Model (CRM), Control
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 26 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 26, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns

NCT01654094
View directory record Official record
Conditions
Burns, Skin Burn Requiring Skin Graft
Interventions
P6 Low Adherent Dressing, Standard of Care (SOC)
Device · Other
Lead sponsor
Milliken Healthcare Products, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Gainesville, Florida • Chapel Hill, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 26, 2026, 5:15 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer

NCT02700776
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Phlebotomy - Blood sampling for GP88 at MM, SOC Tissue biopsy
Other · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years to 64 Years · Female only
Enrollment
417 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 26, 2026, 5:15 AM EDT
Recruiting Early Phase 1 Interventional

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

NCT07609225
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reducing Urban Cervical Cancer Disparities

NCT06416150
View directory record Official record
Conditions
Cervical Cancer, Papilloma Viral Infection
Interventions
Stage 1 SOC, Stage 1 HERS, Stage 2 HERS, Stage 2 HERS+HC, Stage 3 SOC, Stage 3 HERS, Stage 3 HERS+HC, Stage 4 HERS, Stage 4 HERS+HC
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 26, 2026, 5:15 AM EDT
Active, not recruiting Phase 1 Interventional

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

NCT06130826
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Carcinoma
Interventions
Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Immunotherapy, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Withdrawn Phase 1 Interventional

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

NCT07566585
View directory record Official record
Conditions
AML - Acute Myeloid Leukemia, AML With Mutated NPM1, AML, Adult Recurrent
Interventions
SOC+BSB-2002
Drug
Lead sponsor
BlueSphere Bio, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab Adizutecan, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

NCT00323115
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Autologous Dendritic Cell, Temozolomide, Radiotherapy, Dendritic Cell Vaccine
Biological · Drug · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 26, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers

NCT07769502
View directory record Official record
Conditions
Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
Interventions
Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780437
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
88
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 26, 2026, 5:15 AM EDT
Recruiting Phase 4 Interventional

Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers

NCT07089602
View directory record Official record
Conditions
Diabetic Foot, DFU, Diabetic Foot Ulcer, Foot Ulcer, Diabetic, Ulcer Foot, Venous Leg Ulcer, Leg Ulcer, Leg Ulcers Venous, Ulcer
Interventions
Standard of Care DFU, Tri-Membrane Wrap™ DFU, Membrane Wrap™ DFU, Membrane Wrap-Lite™ DFU, Membrane Wrap-Hydro™ DFU, Standard of Care VLU, Tri-Membrane Wrap™ VLU, Membrane Wrap™ VLU, Membrane Wrap-Lite™ VLU, Membrane Wrap-Hydro™ VLU
Other
Lead sponsor
BioLab Holdings
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philidelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 26, 2026, 5:15 AM EDT